Bodiford, Katherine J.

ABSTRACT Background Plasma cell mucositis (PCM) is a rare, chronic inflammatory condition of mucosal surfaces that is likely underdiagnosed and underreported, with limited data on its clinical characteristics, extracavitary involvement, and treatment outcomes. Objectives To characterize the clinical presentation, comorbidities, and treatment patterns of PCM in a cohort of patients from a tertiary care center. Methods We conducted a retrospective cohort study of histopathologically confirmed PCM cases diagnosed at a tertiary care center between 2004 and 2024. Cases were identified based on clinicopathologic correlation demonstrating a polyclonal plasma cell–rich infiltrate. Demographic data, clinical features, comorbidities, laboratory findings, and treatment outcomes were collected and analyzed descriptively. Results Ten patients were included, of whom 7 (70%) were aged ≥ 50 years and 6 (60%) were male. Genital involvement was observed in 6 patients (60%), whereas oral involvement occurred in 4 (40%). Symptom duration exceeded 2 years in 6 patients (60%). Concurrent malignancies were identified in 4 patients (40%), and autoimmune conditions in 2 (20%). Treatment responses were heterogeneous; topical corticosteroids were the most consistently effective therapy, while systemic immunosuppressive agents were required in 3 patients (30%) with variable outcomes. Patch testing identified contact allergens in 2 patients, with improvement following allergen avoidance. Conclusions PCM is a rare and often chronic condition with heterogeneous clinical manifestations and variable therapeutic responses. Genital involvement may be more common than previously recognized. Management remains challenging, highlighting the need for improved understanding of disease pathogenesis and development of more effective treatment strategies.

Abstract Objectives Oral extraintestinal manifestations (OEIMs) of inflammatory bowel disease (IBD) may impact IBD treatment. The aims of this study were to: (1) determine which OEIMs are most prevalent among patients with IBD, (2) investigate the presence of a temporal association between GI luminal disease activity and OEIMs, and (3) determine how often changes in therapeutic management of IBD are needed in the presence of OEIMs. Study Design A retrospective cohort study was performed for adult patients with IBD evaluated between January 2017 and November 2021 with at least 1 oral complaint. Demographic data were collected from the charts of these patients. Kruskal-Wallis test for continuous measures and Fisher’s Exact test for categorical measures were used. Results A total of 116 patients with IBD who had presented with at least 1 oral finding during the study time period were identified. Aphthous ulcers were the most common oral presentation in both Crohn’s disease (CD) (85.1%) and ulcerative colitis (UC) (75.0%). OEIMs were associated with CD activity in the small intestine (P = .004) and colon (P < .001). UC pancolitis was associated with OEIMs (P = .002). In 32.7% of patients, OEIMs led to either an increase in dose or frequency of IBD therapy. In an additional 16.4% of patients, new systemic agents were started because of the OEIMs. Conclusions This study provides evidence that patients with IBD may develop OEIMs synchronous with IBD flares and may require escalation of IBD therapy when OEIMs occur.

BACKGROUND Chromoblastomycosis is an uncommon fungal infection of the skin caused by a variety of dematiaceous fungal species that is typically contracted through direct inoculation into the skin. OBJECTIVE To collect and examine data pertaining to the clinical presentation and management of patients with chromoblastomycosis. METHODS Through a retrospective study, a pathology medical record search was performed from January 2004 to December 2020 at a single institution. RESULTS A total of 9 patients were identified. Seven of 9 cases occurred in solid organ transplant recipients. All cases were located on the extremities. Six of 9 cases were clinically suspected to be squamous cell carcinoma. Seven of 9 cases were treated with surgical excision. Six of 9 patients were treated with oral antifungal medication. Four of 9 patients had received combination therapy. Eight of 9 patients had no recurrence of the disease after treatment. CONCLUSION Chromoblastomycosis presents as verrucous papules or nodules and may clinically and histopathologically mimic squamous cell carcinoma. Immunosuppression is likely a risk factor for the development of chromoblastomycosis. This study highlights the importance of clinical awareness of this disease's clinical presentation and prevalence in immunosuppressed patient populations.